YOLFTbeta
ProQR Therapeutics BV

ProQR Therapeutics BV

PRQR · NASDAQ · Healthcare / Biotechnology

1.41USD+0.05 (+3.68%)

Price History

Full chart

Market Stats

Previous Close1.36
Open1.39
Day Range1.37 – 1.44
52-Week Range1.33 – 3.10
Volume568.64K
Market Cap232.85M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.46
Dividend Yield0.00%
Beta0.06
50-Day Avg1.94
200-Day Avg1.77

About

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Daniel Anton de Boer
  • Employees186
  • HeadquartersZernikedreef 9, Leiden, Netherlands, 2333 CK, USA
  • Websitehttps://www.proqr.com

Leadership

  • Mr. Daniel Anton de BoerFounder, CEO & Executive Director · b. 1983
  • Dr. Gerard Platenburg Ph.D.Co-Founder, Chief Scientific Officer & Executive Director · b. 1964
  • Mr. Dennis HomChief Financial Officer · b. 1975
  • Ms. Sheila SponseleeChief People & Operations Officer · b. 1984
  • Ms. Sarah Cue KielyVice President of Investor Relations & Corporate Communications
  • Dr. Cristina Lopez Lopez M.D., Ph.D.Chief Medical Officer · b. 1976

Financials

Income Statement

Currency: EUR2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue30.00K160.00K313.00K9.41M2.28M-1.53M4.94M1.93M1.03M1.33M3.59M6.51M18.91M15.28M
Growth (%)-+433.33%+95.63%+2905.43%-75.74%-167.00%+423.15%-60.88%-46.77%+29.74%+169.21%+81.25%+190.22%-19.18%
Cost of Revenue583.00K4.59M18.01M482.85K1.28M1.00M983.51K116.82M2.19M-2.48M133.52K-2.60M
Gross Profit-116.00K313.00K8.92M1.00M-2.53M3.96M-114.89M1.03M1.33M3.59M6.51M18.91M12.68M
Gross Margin-72.50%100.00%94.87%43.84%165.49%80.09%-5943.61%100.00%100.00%100.00%100.00%100.00%83.01%
Operating Expense-3.35M16.77M35.93M40.57M37.97M40.25M-57.45M43.40M58.55M68.75M38.37M49.38M54.84M
Operating Income--3.24M-16.46M-27.00M-39.57M-40.50M-36.29M-57.45M-42.37M-57.21M-65.16M-31.86M-30.47M-42.15M
Operating Margin--2024.37%-5259.11%-287.05%-1734.14%2648.66%-734.53%-2971.81%-4117.40%-4285.39%-1812.99%-489.09%-161.18%-275.91%
EBITDA--3.19M-49.70M-84.24M-120.55M-40.93M-35.29M-174.27M-48.44M-54.95M-56.46M-24.10M-24.12M-37.04M
EBITDA Margin--1994.38%-15877.32%-895.55%-5282.52%2676.78%-714.26%-9015.42%-4707.10%-4115.96%-1570.95%-369.93%-127.60%-242.42%
Net Income--3.25M-12.13M-20.83M-39.10M-43.64M-36.89M-56.75M-46.56M-60.74M-64.42M-28.12M-27.76M-40.52M
Net Income Margin--2033.13%-3874.44%-221.45%-1713.54%2853.96%-746.69%-2935.64%-4525.27%-4549.81%-1792.54%-431.67%-146.86%-265.21%
R&D376.00K2.57M10.27M23.40M31.92M31.15M29.51M46.49M38.13M42.22M50.87M25.15M36.36M40.72M
R&D as % of Total Revenue1253.33%1605.62%3280.19%248.76%1398.90%-2037.48%597.33%2405.12%3706.03%3162.55%1415.33%386.06%192.31%266.51%
Interest Expense038.00K265.00K395.00K538.00K596.00K810.00K1.08M2.04M3.40M5.13M1.20M1.08M866.40K
Interest Expense % of Total Revenue0.00%23.75%84.66%4.20%23.58%-38.98%16.39%56.03%198.25%255.06%142.65%18.47%5.70%5.67%

Balance Sheet

Currency: EUR2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets445.62K6.21M139.45M108.75M69.13M63.77M110.23M131.93M120.80M238.33M182.84M152.31M173.92M132.43M
Total Liabilities315.10K6.33M7.07M11.20M13.09M16.54M17.55M26.61M51.61M109.57M111.68M106.59M82.22M74.44M
Total Equity130.52K-122.64K132.38M97.55M56.05M47.27M92.69M105.88M69.85M129.45M71.58M45.72M91.70M57.99M
Cash328.28K5.69M136.42M103.05M62.44M57.76M105.58M125.66M92.79M213.25M101.15M131.37M154.71M108.53M
Total Debt125.25K4.83M3.46M5.26M4.85M8.70M28.14M15.22M41.94M68.66M23.45M21.80M16.08M16.43M
Net Debt-203.03K-859.84K-132.95M-97.80M-57.59M-49.06M-96.19M-110.44M-50.85M-144.60M-77.70M-109.57M-138.63M-92.10M

Cash Flow

Currency: EUR2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--2.33M-14.46M-24.23M-34.22M-34.95M-30.68M-43.97M-47.06M-26.01M-68.51M21.55M-36.39M-52.79M
Investing Cash Flow--137.00K-1.23M-1.32M-2.54M-121.00K-312.00K-580.00K-924.00K-425.00K-702.00K4.28M-4.07M-1.02M
Financing Cash Flow808.00K6.35M119.88M1.62M357.00K26.64M88.65M50.20M14.50M136.83M-30.89M-2.27M70.28M-1.84M
Capital Expenditure0137.00K1.23M1.32M2.54M121.00K312.00K580.00K924.00K484.00K708.00K1.37M1.42M1.02M
Free Cash Flow--2.47M-15.69M-25.56M-36.76M-35.07M-30.99M-44.55M-47.98M-26.50M-69.22M20.18M-37.81M-53.81M
Dividends Paid---00000------
FCF to OCF-105.87%108.53%105.46%107.42%100.35%101.02%101.32%101.96%101.86%101.03%93.64%103.90%101.93%
Dividend Paid to FCF---0.00%0.00%0.00%0.00%0.00%------

Earnings

Report DateNov 24, 2014Feb 26, 2015May 21, 2015Aug 19, 2015Nov 23, 2015Feb 17, 2016May 18, 2016Aug 17, 2016Nov 14, 2016Feb 28, 2017May 17, 2017Aug 16, 2017Nov 20, 2017Feb 28, 2018May 9, 2018Aug 8, 2018Nov 7, 2018Feb 27, 2019May 8, 2019Aug 7, 2019Nov 6, 2019Feb 26, 2020May 7, 2020Aug 6, 2020Nov 16, 2020Feb 25, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Feb 24, 2022May 5, 2022Aug 4, 2022Nov 9, 2022Mar 29, 2023May 16, 2023Aug 3, 2023Nov 7, 2023Mar 13, 2024May 9, 2024Aug 8, 2024Nov 7, 2024Mar 13, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Feb 19, 2026May 12, 2026Aug 20, 2026Nov 5, 2026
EPS Estimate-0.61-0.29-0.18-0.34-0.38-0.37-0.41-0.48-0.54-0.53-0.51-0.51-0.50-0.48-0.40-0.47-0.31-0.26-0.38-0.43-0.38-0.35-0.36-0.35-0.39-0.25-0.30-0.27-0.24-0.12-0.24-0.22-0.23-0.16-0.10-0.12-0.130.01-0.16-0.17-0.14-0.09-0.16-0.08-0.17-0.09-0.18-0.14-0.11
EPS Actual-0.53-0.100.01-0.41-0.29-0.29-0.50-0.48-0.46-0.40-0.50-0.55-0.49-0.46-0.40-0.27-0.21-0.38-0.40-0.34-0.34-0.39-0.35-0.09-0.31-0.26-0.30-0.28-0.24-0.28-0.20-0.23-0.29-0.16-0.13-0.11-0.08-0.07-0.10-0.04-0.08-0.09-0.11-0.14-0.12-0.09-0.15-0.10-
Surprise13.11%65.52%105.56%-20.59%23.68%21.62%-21.95%0.00%14.81%24.53%1.96%-7.84%2.00%4.17%0.00%42.55%32.26%-46.15%-5.26%20.93%10.53%-11.43%2.78%74.29%20.51%-4.00%0.00%-3.70%0.00%-133.33%16.67%-4.55%-26.09%0.00%-30.00%8.33%38.46%-800.00%37.50%76.47%42.86%4.86%31.25%-75.00%29.41%-4.63%16.67%28.57%-
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-market-Pre-market

Key Statistics & Ratios

Market Cap232.85M
Enterprise Value123.35M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales12.64
Price / Book2.63
EPS-0.46
Book Value0.8426
Revenue (TTM)18.42M
Gross Profit (TTM)18.42M
EBITDA-41.90M
Profit Margin-228.18%
Operating Margin-100.72%
Return on Equity-57.40%
Return on Assets-19.76%
Shares Outstanding141.12M
Shares Float91.44M
Beta0.06
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 8 analystsTarget 8.22
  • Strong Buy
    6
  • Buy
    2

Ownership Breakdown

Institutions
54.50%
Insiders
17.16%
Retail / Other
28.34%

Top Institutional Holders

  • Adage Capital Partners Gp LLC
    9.02M6.39%
  • Aberdeen Group PLC
    8.93M6.33%
  • Affinity Asset Advisors, LLC
    5.54M3.93%
  • Privium Fund Management B.V.
    5.47M3.87%
  • Kynam Capital Management, LP
    1.57M1.11%
  • Dafna Capital Management LLC
    1.53M1.08%
  • Squadron Capital Management LLC
    1.51M1.07%
  • Ikarian Capital, LLC
    1.49M1.06%
  • Morgan Stanley - Brokerage Accounts
    1.30M0.92%
  • Junked Platinum Investment Management Ltd
    1.24M0.88%
  • Citadel Advisors Llc
    1.18M0.84%
  • Two Sigma Investments LLC
    1.14M0.81%
  • Eversept Partners, LP
    1.02M0.72%
  • Diadema Partners LP
    926.02K0.66%
  • Point72 Asset Management, L.P.
    755.84K0.54%
  • Delaware Management Holdings Inc
    620.00K0.44%

Top Fund Holders

  • abrdn World Healthcare
    6.31M4.47%
  • abrdn Life Sciences Investors
    2.62M1.86%
  • Beleggingsfonds Hoofbosch
    800.00K0.57%
  • Nomura Healthcare Fund Class I
    620.00K0.44%